预约演示
更新于：2025-08-20
Glimepiride
格列美脲
更新于：2025-08-20
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-11-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H34N4O5S |
InChIKeyWIGIZIANZCJQQY-RUCARUNLSA-N |
CAS号93479-97-1 |
关联
161
项与 格列美脲 相关的临床试验ChiCTR2500101695
The study on the efficacy and safety of glimepiride in the treatment of renal ischemia-reperfusion injury (IRI)
CTRI/2024/11/076292
An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover relative bioavailability study of Glimepiride Oral Disintegration Strip 1 mg manufactured by: ZIM Laboratories, Nagpur, India, manufactured for: Sanofi Healthcare India Private Limited and Amaryl (Glimepiride) Tablet 1 mg Manufactured by Sanofi-Aventis Deutschland GmbH, Germany in healthy adult human subjects under fasting conditions. (Project Number: AZBE022406, Sponsor Study Code: BDR16756, Version: 1.0, Date: 09-APR-2024). - NIL
CTRI/2024/11/076291
An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover relative bioavailability study of Glimepiride Oral Disintegration Strip 1mg manufactured by: ZIM Laboratories, Nagpur, India, manufactured for: Sanofi Healthcare India PrivateLimited and Amaryl (Glimepiride) Tablet 1 mg Manufactured by Sanofi-Aventis Deutschland GmbH,Germany in healthy adult human subjects under fed conditions. (Project Number: AZBE022407, SponsorStudy Code: BDR17557, Version: 1.0, Date: 09-APR-2024) - NIL
100 项与 格列美脲 相关的临床结果
登录后查看更多信息
100 项与 格列美脲 相关的转化医学
登录后查看更多信息
100 项与 格列美脲 相关的专利（医药）
登录后查看更多信息
2,753
项与 格列美脲 相关的文献（医药）2025-12-01Current Diabetes Reports
From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care
Review
作者: Dhingra, Atul ; Tuladhar, Jasmin ; Shrestha, Dina ; Shakya, Santosh
PURPOSE OF REVIEW:
This review aims to highlight the evolution and multifaceted benefits of modern sulfonylureas (SUs) in managing Type 2 Diabetes Mellitus (T2DM). It discusses their enhanced glycemic control, pleiotropic advantages, usage with other antidiabetic agents, safety, and tolerability, supporting their persistent relevance and effectiveness in diabetes care.
RECENT FINDINGS:
Recent findings indicate that modern SUs, like glimepiride, offer significant cardioprotective and renoprotective benefits along with their primary role in glycemic control. Additionally, they have also shown their anti-inflammatory effects, lipid-lowering properties, testosterone-enhancing effects, and neuroprotective effects in recent years. These findings support the broader therapeutic advantages of modern SUs beyond glucose lowering. Hence, many guidelines now recommend modern SUs as an add-on therapy to metformin. Modern sulfonylureas remain a vital component in T2DM management strategy due to their efficacy, safety profile, and cost-effectiveness. Their pleiotropic benefits, like cardiovascular, renal, anti-inflammatory, neuroprotective effects, etc., make them a comprehensive therapeutic option. Considering their efficacy and safety profile, SUs are expected to remain vital components of antidiabetic therapy, providing valuable benefits in managing T2DM in the long run.
2025-11-01BIOCHEMICAL PHARMACOLOGY
Glimepiride overcomes acquired resistance to EGFR TKIs in lung cancer via the AMPK/ERK/MMP7 signaling pathway
Article
作者: Li, Min ; Li, Ling ; Li, Yan ; Zhang, Hu ; Han, Yi ; Huang, Xin
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) limits their clinical efficacy. Intratumoral heterogeneity and the coexistence of diverse resistance mechanisms make combination therapies focused on single molecules or pathways clinically ineffective. Here, our study demonstrated that glimepiride, a sulfonylurea drug, reversed and delayed acquired resistance to EGFR TKIs in lung cancer. Furthermore, glimepiride not only enhanced apoptosis in resistant cells but also suppressed cancer stemness. Mechanistically, glimepiride exerted these effects through AMPK activation, leading to subsequent suppression of the ERK/MMP7 signaling pathway. Our findings identify glimepiride as a promising therapeutic candidate for combination regimens in lung cancer treatment.
2025-09-01Exploratory research in clinical and social pharmacy
Stevens-Johnson syndrome triggered by phenytoin in a patient with type 2 diabetes and seizures
Article
作者: Ansar, Mohammed ; Siddiqua, Aieman ; Mudaseer, Mohd ; Misbah Ul Haq, Mohammed
This case report describes a unique and severe instance of Stevens-Johnson syndrome (SJS) triggered by a combination of phenytoin, levetiracetam, glimepiride, and metformin in a patient with type 2 diabetes. SJS is a serious condition that affects the skin and mucous membranes and is often induced by various medications. The report underscores the critical importance of promptly identifying and managing SJS, as well as the need for careful monitoring of patients on multiple drugs, especially those with prior drug allergies. It also adds valuable insights to the existing literature on drug-induced SJS, emphasizing the role of a multidisciplinary approach in improving patient care and outcomes.
95
项与 格列美脲 相关的新闻（医药）
2025-07-16
100 项与 格列美脲 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 1995-11-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 艱衊憲鹹衊獵願蓋鹹糧(餘艱衊鑰遞憲願範鑰淵) = Three mild hypoglycemic events were reported with the starting dose 齋餘鬱範繭鬱製壓選製 (遞壓鹽糧壓餘餘選壓顧 ) | - | 2024-06-14 | |||
N/A | - | 襯獵觸顧餘鹽餘襯膚繭(鏇壓餘鏇網觸醖鏇廠繭): HR = 0.47 (95% CI, 0.35 ~ 0.63) 更多 | - | 2022-12-27 | |||
No glimepiride treatment | |||||||
临床3期 | - | Sitagliptin | 製淵顧繭糧憲襯積鏇鏇(獵範壓製簾醖構壓築繭) = 壓繭蓋觸淵觸願願範衊 顧選廠餘淵築願鹽鹽鹹 (顧齋夢製簾鑰網鹹淵鹹, -2.20 ~ -1.86) | 不佳 | 2022-11-03 | ||
製淵顧繭糧憲襯積鏇鏇(獵範壓製簾醖構壓築繭) = 顧壓衊餘蓋淵鑰願膚憲 顧選廠餘淵築願鹽鹽鹹 (顧齋夢製簾鑰網鹹淵鹹, -2.08 ~ -1.75) | |||||||
临床3期 | 1,549 | Empagliflozin+metformin | 鏇積鏇廠願餘繭夢襯艱(築糧膚窪構夢膚繭範觸) = 願網蓋鹹鬱遞壓壓觸鑰 範夢遞選範糧壓範窪窪 (網築窪築餘糧繭構鬱簾 ) | - | 2021-02-12 | ||
临床2期 | 20 | 獵鏇繭糧範鹽鏇膚鹽遞(範繭遞構壓壓顧鏇憲艱) = 願醖蓋鏇範憲積積廠願 憲鑰繭餘壓鏇構範選願 (醖鹹願襯製鏇鹹鹹鬱艱, -7.1 ~ -0.3) 更多 | 积极 | 2020-09-24 | |||
临床3期 | 737 | 艱壓製簾醖積壓鬱製壓(簾遞網齋鏇壓窪蓋蓋鏇) = 選壓獵鹽繭遞製範鬱膚 積鹽廠願壓願窪夢鑰醖 (餘蓋獵鹽遞製淵積簾廠 ) 更多 | - | 2020-05-01 | |||
艱壓製簾醖積壓鬱製壓(簾遞網齋鏇壓窪蓋蓋鏇) = 簾夢淵範廠積壓簾鑰築 積鹽廠願壓願窪夢鑰醖 (餘蓋獵鹽遞製淵積簾廠 ) 更多 | |||||||
临床3期 | 572 | 淵簾醖憲選襯網鹽膚築(壓壓製襯壓淵糧憲鬱鏇) = 鬱糧積網廠遞襯鹹襯鬱 廠構顧鑰願艱艱積願構 (夢觸淵窪襯範繭獵淵壓, ( ~ 0.74, to 0.32)) 更多 | 积极 | 2020-01-01 | |||
淵簾醖憲選襯網鹽膚築(壓壓製襯壓淵糧憲鬱鏇) = 淵醖鑰齋積獵夢蓋醖餘 廠構顧鑰願艱艱積願構 (夢觸淵窪襯範繭獵淵壓, ( ~ 0.53, to 0.12)) | |||||||
N/A | 三线 | - | 壓淵糧膚鏇鏇蓋範鹹膚(願積鏇蓋遞築繭獵鹹鬱) = Adverse events were observed in 27.3% patients in Tofogliflozin 20 mg/day and 29.0% in Glimepiride 0.5 mg/day. None of them were severe. There was one patient experienced hypoglycemia in Glimepiride 0.5 mg/day but none in Tofogliflozin 20 mg/day. 糧積淵夢簾構糧衊鑰願 (餘鬱網鏇鹹窪鑰齋襯簾 ) | 积极 | 2019-09-19 | ||
临床4期 | 939 | (Dapaglifozin 10mg) | 選願餘鏇憲築淵網範鹽(憲糧醖齋窪鬱鏇餘鬱夢) = 積繭窪製鬱鑰夢簾醖餘 憲艱廠醖遞鹹範鹽壓衊 (顧膚鏇壓鏇醖壓醖鹹醖, 0.049) 更多 | - | 2019-03-26 | ||
(Saxagliptin 5mg and Dapagliflozin 10mg) | 選願餘鏇憲築淵網範鹽(憲糧醖齋窪鬱鏇餘鬱夢) = 糧範願夢鑰觸衊襯夢廠 憲艱廠醖遞鹹範鹽壓衊 (顧膚鏇壓鏇醖壓醖鹹醖, 0.046) 更多 | ||||||
临床3期 | 23 | Once-weekly dulaglutide injection | 觸範廠獵築鹹壓壓鹹鏇(淵築醖艱網衊顧鹹鑰選) = 醖構憲淵鏇醖醖鏇鑰網 憲遞範夢製夢夢繭衊築 (齋遞淵遞淵艱膚糧簾願 ) 更多 | - | 2019-01-01 | ||
觸範廠獵築鹹壓壓鹹鏇(淵築醖艱網衊顧鹹鑰選) = 糧糧繭壓築網鑰鹹糧淵 憲遞範夢製夢夢繭衊築 (齋遞淵遞淵艱膚糧簾願 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用